Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

Por Davidoff, A M, Iglehart, J D, Marks, J R
Publicado em 1992

HIV-1-associated thrombocytopenia. The role of splenectomy.

Por Tyler, D S, Shaunak, S, Bartlett, J A, Iglehart, J D
Publicado em 1990

Genetic basis for p53 overexpression in human breast cancer.

Por Davidoff, A M, Humphrey, P A, Iglehart, J D, Marks, J R
Publicado em 1991

The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.

Por Duhaylongsod, F G, Gottfried, M R, Iglehart, J D, Vaughn, A L, Wolfe, W G
Publicado em 1995

Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.

Por Kong, F M, Anscher, M S, Murase, T, Abbott, B D, Iglehart, J D, Jirtle, R L
Publicado em 1995

Overestimation of hereditary breast cancer risk.

Por Iglehart, J D, Miron, A, Rimer, B K, Winer, E P, Berry, D, Shildkraut, M J
Publicado em 1998

Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features.

Por Skinner, M A, Swain, M, Simmons, R, McCarty, K S, Sullivan, D C, Iglehart, J D
Publicado em 1988

Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases.

Por Coveney, E, Weltz, C R, Greengrass, R, Iglehart, J D, Leight, G S, Steele, S M, Lyerly, H K
Publicado em 1998

Bcl10 is not a target for frequent mutation in human carcinomas

Por Lambers, A R, Gumbs, C, Ali, S, Marks, J R, Iglehart, J D, Berchuck, A, Futreal, P A
Publicado em 1999

Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

Por Vaughn, J P, Iglehart, J D, Demirdji, S, Davis, P, Babiss, L E, Caruthers, M H, Marks, J R
Publicado em 1995

Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.

Por Vaughn, J P, Stekler, J, Demirdji, S, Mills, J K, Caruthers, M H, Iglehart, J D, Marks, J R
Publicado em 1996

Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.

Por Marks, J R, Humphrey, P A, Wu, K, Berry, D, Bandarenko, N, Kerns, B J, Iglehart, J D
Publicado em 1994

An ultrastructural analysis of breast carcinoma presenting as isolated axillary adenopathy.

Por Iglehart, J D, Ferguson, B J, Shingleton, W W, Sabiston, D C, Silva, J S, Fetter, B F, McCarty, K S
Publicado em 1982

Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.

Por Peters, K. G., Coogan, A., Berry, D., Marks, J., Iglehart, J. D., Kontos, C. D., Rao, P., Sankar, S., Trogan, E.
Publicado em 1998

Activated protooncogenes in human lung tumors from smokers.

Por Reynolds, S H, Anna, C K, Brown, K C, Wiest, J S, Beattie, E J, Pero, R W, Iglehart, J D, Anderson, M W
Publicado em 1991

Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy.

Por Anscher, M S, Jones, P, Prosnitz, L R, Blackstock, W, Hebert, M, Reddick, R, Tucker, A, Dodge, R, Leight, G, Iglehart, J D
Publicado em 1993

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers

Por Birkbak, N J, Li, Y, Pathania, S, Greene-Colozzi, A, Dreze, M, Bowman-Colin, C, Sztupinszki, Z, Krzystanek, M, Diossy, M, Tung, N, Ryan, P D, Garber, J E, Silver, D P, Iglehart, J D, Wang, Z C, Szuts, D, Szallasi, Z, Richardson, A L
Publicado no Ann Oncol (2018)